| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
49,450,000 |
| Market
Cap: |
1.52(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$25.5 - $42.47 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 623 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Pacira BioSciences is a holding company. Through its subsidiaries, Co. is focused on non-opioid pain management. Co. has three commercialized non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting, local analgesic approved for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, corticosteroid injection indicated for the management of OA knee pain; and ioveradeg®, a handheld device for delivering immediate, long-acting, drug-free pain control using controlled doses of cold temperature to a targeted nerve.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
119,323 |
119,323 |
189,781 |
290,198 |
| Total Sell Value |
$3,656,226 |
$3,656,226 |
$6,334,261 |
$12,063,571 |
| Total People Sold |
1 |
1 |
15 |
16 |
| Total Sell Transactions |
3 |
3 |
34 |
58 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Stack David M |
CEO and Chairman |
• • – |
2018-08-15 |
4 |
OE |
$5.49 |
$149,079 |
D/D |
14,091 |
124,745 |
|
- |
|
| Dunker Kristen Marie |
CAO and General Counsel |
• – – |
2018-08-14 |
4 |
AS |
$47.04 |
$224,522 |
D/D |
(4,773) |
22,374 |
|
- |
|
| Riker Lauren Bullaro |
Vice President, Finance |
• – – |
2018-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
12,141 |
|
- |
|
| Longenecker John P Phd |
Director |
– • – |
2018-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
782 |
5,927 |
|
- |
|
| Kronenfeld Mark A. |
Director |
– • – |
2018-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
782 |
7,577 |
|
- |
|
| Hastings Paul J |
Director |
– • – |
2018-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
782 |
3,529 |
|
- |
|
| Pace Gary W |
Director |
– • – |
2018-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
782 |
24,319 |
|
- |
|
| Greenstreet Yvonne |
Director |
– • – |
2018-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
782 |
5,627 |
|
- |
|
| Dunker Kristen Marie |
CAO and General Counsel |
• – – |
2018-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
7,875 |
27,147 |
|
- |
|
| Reinhart Charles A. Iii |
Chief Financial Officer |
• – – |
2018-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
13,042 |
|
- |
|
| Scranton Richard |
Chief Scientific Officer |
• – – |
2018-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
7,875 |
20,101 |
|
- |
|
| Brege Laura |
Director |
– • – |
2018-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
782 |
4,627 |
|
- |
|
| Froimson Mark |
Director |
– • – |
2018-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
782 |
882 |
|
- |
|
| Laranjeira Charles Anthony |
SVP, Technical Operations |
• – – |
2018-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
5,238 |
|
- |
|
| Stack David M |
CEO and Chairman |
• • – |
2018-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
28,375 |
110,415 |
|
- |
|
| Stack David M |
CEO and Chairman |
• • – |
2018-06-07 |
4 |
AS |
$36.63 |
$360,984 |
D/D |
(9,791) |
82,040 |
|
- |
|
| Stack David M |
CEO and Chairman |
• • – |
2018-06-06 |
4 |
AS |
$35.61 |
$306,780 |
D/D |
(8,615) |
91,831 |
|
- |
|
| Riker Lauren Bullaro |
Vice President, Finance |
• – – |
2018-06-04 |
4 |
S |
$33.02 |
$26,449 |
D/D |
(801) |
9,641 |
|
- |
|
| Hastings Paul J |
Director |
– • – |
2018-06-04 |
4 |
S |
$33.90 |
$26,137 |
D/D |
(771) |
2,747 |
|
- |
|
| Dunker Kristen Marie |
CAO and General Counsel |
• – – |
2018-06-04 |
4 |
S |
$33.02 |
$67,361 |
D/D |
(2,040) |
19,272 |
|
- |
|
| Reinhart Charles A. Iii |
Chief Financial Officer |
• – – |
2018-06-04 |
4 |
S |
$33.02 |
$23,378 |
D/D |
(708) |
8,042 |
|
- |
|
| Scranton Richard |
Chief Scientific Officer |
• – – |
2018-06-04 |
4 |
S |
$33.02 |
$45,138 |
D/D |
(1,367) |
12,226 |
|
- |
|
| Weiland Robert J. |
Chief Commercial Officer |
• – – |
2018-06-04 |
4 |
S |
$33.02 |
$12,316 |
D/D |
(373) |
5,088 |
|
- |
|
| Stack David M |
CEO and Chairman |
• • – |
2018-05-15 |
4 |
AS |
$33.69 |
$844,781 |
D/D |
(25,000) |
100,446 |
|
- |
|
| Stack David M |
CEO and Chairman |
• • – |
2018-05-15 |
4 |
OE |
$5.49 |
$190,450 |
D/D |
25,000 |
125,446 |
|
- |
|
781 Records found
|
|
Page 16 of 32 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.44 (1.45%) 
